On Tuesday, Shares of Dynavax Technologies Corporation (NASDAQ:DVAX), added 15.85% and closed at $4.75 in the last trading session. The last trading range of the stock ranges between $3.20 and $4.80. Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel vaccines and therapeutics in the United States. Its development programs focuses on vaccine adjuvants, cancer immunotherapy, and autoimmune and inflammatory diseases. The companys lead products include HEPLISAV-B, an investigational adult hepatitis B vaccine, which is in Phase III clinical trials; and SD-101, a C Class CpG TLR9 agonist for the treatment of cancer, which is in Phase I/II multicenter clinical trial. Its product portfolio also comprises AZD1419 for the treatment of asthma, which is in Phase II clinical trial; DV1179, a TLR7/9 inhibitor that is in Phase Ib/IIa for the treatment of autoimmune and inflammatory conditions; and DV281 and CpG-Nanoparticles, which are in preclinical studies for cancer immunotherapy. It has a research partnershipand license agreement with AstraZeneca AB to conduct a Phase IIa safety and efficacy trial of AZD1419 for the treatment of asthma; and planned alliance with GlaxoSmithKline to discover, develop, and commercialize TLR inhibitors.
Rex Energy Corporation (NASDAQ:REXX), dropped -18.20% and closed at $0.286 in the last trading session. The last trading range of the stock ranges between $0.23 and $0.38. The company’s Market capitalization is $25.02 Billion with the total Outstanding Shares of 97.88 million. Rex Energy Corporation (REXX) recently declared its third quarter 2016 operational and financial results.
Third Quarter Financial Results
Unless otherwise noted, results of continuing operations are presented apart from the results of the company’s Illinois Basin assets, which have been classified as suspended operations, for all periods presented.
Operating revenue from continuing operations for the three and nine months ended September 30, 2016 was $34.0 million and $91.0 million, respectively, which represents a boost of 15% and a decrease of 18% over the same periods in 2015. Commodity revenues, counting settlements from derivatives, for the three and nine months ended September 30, 2016 were $36.3 million and $123.7 million, a decrease of 19% and 18% for the same periods in 2015, respectively. Commodity revenues from condensate and natural gas liquids (NGLs), counting settlements from derivatives, represented 50% of total commodity revenues for the three months ended September 30, 2016.
FLIR Systems, Inc. (NASDAQ:FLIR), dropped -0.54% and closed at $35.28 in the last trading session. The last trading range of the stock ranges between $34.75 and $35.97. During the 52-week trading session the minimum price at which share price traded, registered at $26.13 and reached to max level of $35.97. FLIR Systems, Inc. ( NASDAQ : FLIR ) declared recently that it has successfully accomplished its formerly declared acquisition of the business of Point Grey Research Inc., for an aggregate purchase price of $259 million in cash, or an enterprise value of $256 million apart from Point Grey’s closing cash balance.
Founded in 1997 and based in Richmond, British Columbia, Point Grey is a global leader in the development of advanced visible imaging cameras and solutions that are used in industrial automation systems, medical diagnostic equipment, people counting systems, intelligent traffic systems, military and defense products, and advanced mapping systems. Point Grey designs, manufactures, and distributes its cameras and related software to a global base of customers that build systems for improving the efficiency, quality, analysis, and safety of a wide range of processes and products.